Evidence map›Paper›PMID 25152629›Full record

ArticleJournal of pain research2014

Efficacy and safety profile of combination of tramadol-diclofenac versus tramadol-paracetamol in patients with acute musculoskeletal conditions, postoperative pain, and acute flare of osteoarthritis and rheumatoid arthritis: a Phase III, 5-day open-label study.

Ajay S Chandanwale, Subramanian Sundar, Kaliaperumal Latchoumibady, Swati Biswas, Mukesh Gabhane, Manoj Naik, Kamlesh Patel

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Journal of pain research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04968158 (Confirmatory Efficacy and Safety Study of the Fixed-dose Combination of Etoricoxib / Tramadol Versus Acetaminophen / Tramadol for the Management of Acute Low Back Pain.), which is not on this map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
3.6field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04968158 phase3completednot on this mapstarted 2021, after this paper: background citation

Confirmatory Efficacy and Safety Study of the Fixed-dose Combination of Etoricoxib / Tramadol Versus Acetaminophen / Tramadol for the Management of Acute Low Back Pain.

TypeinterventionalSponsorLaboratorios Silanes S.A. de C.V.Ran2021 to 2022Enrolled124ConditionsAcute Low Back PainArmsEtoricoxib 90 mg / Tramadol 50 mg, Acetaminophen 325 mg / Tramadol 37.5 mg
3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Tramadol Prescription over a 4-Year Period in the USA.Current pain and headache reports · 2019
    Review
  13. Review
  14. Article
  15. Osteoarthritis year in review 2015: clinical.Osteoarthritis and cartilage · 2016
    Review
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Ajay S ChandanwaleDepartment of Orthopedics & Traumatology, Byramjee Jeejeebhoy Medical College and Sassoon General Hospital, Pune, Maharashtra, India.
Subramanian SundarVasantha Subramanian Hospital, Chennai, Tamil Nadu, India.
Kaliaperumal LatchoumibadyVijay Hospital, Pondicherry, India.
Swati BiswasMedical Services Department, Abbott Healthcare Pvt Ltd, Mumbai, India.
Mukesh GabhaneMedical Services Department, Abbott Healthcare Pvt Ltd, Mumbai, India.
Manoj NaikClinical Research Department, Abbott Healthcare Pvt Ltd, Mumbai, India.
Kamlesh PatelMedical Services Department, Abbott Healthcare Pvt Ltd, Mumbai, India.
Abbott (India) · INB. J. Medical College & Sassoon Hospital · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveWe aimed to evaluate the safety and efficacy of a fixed-dose combination (FDC) of tramadol and diclofenac versus a standard approved FDC of tramadol and paracetamol, in patients with acute moderate to severe pain.

methodsA total of 204 patients with moderate to severe pain due to acute musculoskeletal conditions (n=52), acute flare of osteoarthritis (n=52), acute flare of rheumatoid arthritis (n=50), or postoperative pain (n=50) were enrolled in the study at baseline. Each disease category was then randomized to receive either of two treatments for 5 days: group A received an FDC of immediate-release tramadol hydrochloride (50 mg) and sustained-release diclofenac sodium (75 mg) (one tablet, twice daily), and group B received an FDC of tramadol hydrochloride (37.5 mg) and paracetamol (325 mg) (two tablets every 4-6 hours, up to a maximum of eight tablets daily). The primary efficacy end points were reductions in pain intensity from baseline at day 3 and day 5 as assessed by a Visual Analog Scale (VAS) score.

resultsGroup A showed a significant reduction in the VAS score for overall pain from baseline on day 3 (P=0.001) and day 5 (P<0.0001) as compared with group B. The combination of tramadol-diclofenac resulted in few mild to moderate adverse events (nausea, vomiting, epigastric pain, and gastritis), which required minimal management, without any treatment discontinuation. The number of adverse events in group A was nine (8.82%) compared with 22 (21.78%) in group B, after 5 days of treatment.

conclusionAn FDC of tramadol-diclofenac showed a significantly greater reduction in pain intensity and was well tolerated compared with tramadol-paracetamol, resulting in better analgesia in patients suffering from moderate to severe pain due to acute musculoskeletal conditions, postoperative pain following orthopedic surgery, or acute flare of osteoarthritis and rheumatoid arthritis.

Indexed as

moderate to severe paintramadol and diclofenac combination

Identifiers

PMID25152629
PMCPMC4140236
OpenAlexW1995547228

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.